Not all products or features are available in all markets.

  • Change country/language

    Looks like you’re in {} — you’re on the {} site.

    Cancel

    Country and language selected

    You are being redirected to the {} site. Products and services availability vary by country. Do you wish to continue?

    Continue
    Cancel

Contrast-Enhanced MRI: Moving Beyond Gadolinium

Tuesday, 1 December 12-1pm

Dec. 1, 2026 | 12.00 p.m. -13.00 p.m. CT Industry Expert Theater, South Hall A, Level 3, Booth 2384    

MR contrast agents have played an important role in diagnostic imaging for decades, with gadolinium-based contrast agents routinely used in radiology departments around the world

 

Join us to reflect on how far MR contrast has come and explore where it could go next.

 

The session will look back at the introduction and evolution of gadolinium-based contrast agents, their established role in clinical practice, and advances that have shaped their use today.

 

The faculty will then explore some of the considerations influencing the evolving MR contrast landscape, including safety, gadolinium retention and environmental impact, and discuss how evidence and regulatory developments have informed clinical practice.

 

Finally, the session will look beyond gadolinium, exploring the unmet needs and scientific thinking driving research into alternative approaches to MR contrast, together with an update on emerging innovation and clinical research.

Program

Gadolinium agents - Where are we now today?

Dr Mukesh Harisinghani

Massachusetts General Hospital, Boston, Massachusetts

Why look beyond gadolinium?

Dr Robert McDonald

Mayo Clinic, Rochester, Minnesota

Development of a novel macrocyclic manganese-based contrast agent (MBCA)

Dr Paul Evans

Head of R&D, Pharmaceutical Diagnostics, GE HealthCare